Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CMPX
stocks logo

CMPX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.095
-14.05%
--
--
-0.110
-8.33%
--
--
-0.105
-25%
Estimates Revision
The market is revising No Change the revenue expectations for Compass Therapeutics, Inc. (CMPX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 61.05%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-17.04%
In Past 3 Month
Stock Price
Go Up
up Image
+61.05%
In Past 3 Month
Wall Street analysts forecast CMPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPX is 15.33 USD with a low forecast of 10.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast CMPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPX is 15.33 USD with a low forecast of 10.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.540
sliders
Low
10.00
Averages
15.33
High
24.00
Current: 5.540
sliders
Low
10.00
Averages
15.33
High
24.00
Canaccord
John Newman
Buy
initiated
$10
2025-12-03
New
Reason
Canaccord
John Newman
Price Target
$10
2025-12-03
New
initiated
Buy
Reason
Canaccord analyst John Newman initiated coverage of Compass Therapeutics with a Buy rating and $10 price target.
Guggenheim
Michael Schmidt
Buy
maintain
$10 -> $12
2025-08-12
Reason
Guggenheim
Michael Schmidt
Price Target
$10 -> $12
2025-08-12
maintain
Buy
Reason
Guggenheim analyst Michael Schmidt raised the firm's price target on Compass Therapeutics to $12 from $10 and keeps a Buy rating on the shares. Q2 results included "a positive pipeline update and new clinical data," says the analyst, who notes that management is now officially guiding to announcing the final PFS and OS analysis of the ongoing COMPANION-002 Phase 2/3 trial of tovecimig in second-line and later biliary tract cancer in Q1 of 2026, versus Q4 of 2025 previously. The firm's raised target reflects the addition of highly probability-of-success-adjusted value for CTX-8371 and incrementally higher conviction on tovecimg, the analyst noted.
Raymond James
Sean McCutcheon
Outperform
initiated
$9
2025-07-01
Reason
Raymond James
Sean McCutcheon
Price Target
$9
2025-07-01
initiated
Outperform
Reason
Raymond James analyst Sean McCutcheon resumed coverage of Compass Therapeutics with an Outperform rating and $9 price target. Tovecimig has demonstrated superiority on response rate to its comparator arm in the Phase 3 COMPANION-002 study, notes the analyst, who believes it will hit statistical significance on progression-free survival with a U.S. approval in second-line biliary tract cancer during 2026. Should Tovecimig get approved, the firm thinks the launch of the drug will be "strong given the low bar" and lack of efficacy for standard chemotherapy regimens in the roughly 60% of second-line BTC patients without targetable genomic alterations, the analyst added.
Guggenheim
Buy
downgrade
$12 -> $10
2025-05-09
Reason
Guggenheim
Price Target
$12 -> $10
2025-05-09
downgrade
Buy
Reason
Guggenheim lowered the firm's price target on Compass Therapeutics to $10 from $12 and keeps a Buy rating on the shares. After the quarterly report, the firm updated its model to account for Q1 results and refined launch timing assumptions for tovecimig, the analyst tells investors.
Guggenheim
Michael Schmidt
Strong Buy
Reiterates
n/a
2025-04-22
Reason
Guggenheim
Michael Schmidt
Price Target
n/a
2025-04-22
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$32
2025-04-21
Reason
D. Boral Capital
Jason Kolbert
Price Target
$32
2025-04-21
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Compass Therapeutics Inc. (CMPX.O) is -13.08, compared to its 5-year average forward P/E of -6.29. For a more detailed relative valuation and DCF analysis to assess Compass Therapeutics Inc. 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.29
Current PE
-13.08
Overvalued PE
-3.57
Undervalued PE
-9.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.30
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.60
Undervalued EV/EBITDA
-6.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
25.66
Current PS
0.00
Overvalued PS
148.70
Undervalued PS
-97.37
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CMPX News & Events

Events Timeline

(ET)
2025-11-05
07:34:36
Compass Therapeutics announces Q3 earnings per share of 8 cents, below consensus estimate of 13 cents.
select
2025-11-04 (ET)
2025-11-04
09:08:22
Compass Therapeutics unveils preclinical findings for CTX-10726
select
2025-08-13 (ET)
2025-08-13
06:15:31
Compass Therapeutics 33.3M share Spot Secondary priced at $3.00
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
12-03Yahoo Finance
Wednesday's Key Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy's, and More

  • Market Rally: After a tough Monday, major stock indices and cryptocurrencies saw a significant rally on Tuesday, driven by optimism surrounding a potential interest rate cut by the Federal Reserve.

  • Interest Rate Expectations: The probability of a Fed rate cut next week has risen to 80%, influencing market sentiment and contributing to a decline in bond yields.

  • Energy and Precious Metals Decline: The energy sector and precious metals like gold and silver experienced price drops due to a risk-off mood in the market, with oversupply concerns and profit-taking by traders.

  • Analyst Upgrades and Downgrades: Various stocks received analyst upgrades and downgrades, highlighting shifts in market sentiment and investment strategies, with notable changes for companies like American Eagle Outfitters and Uber Technologies.

[object Object]
Preview
4.0
12-03Benzinga
Linde Analyst Starts Coverage Optimistically; Check Out the Top 5 Initiations for Wednesday

  • Analyst Coverage Initiations: Several Wall Street analysts have initiated coverage on various companies, providing Buy and Outperform ratings along with price targets.

  • Traws Pharma, Inc.: HC Wainwright & Co. analyst Brandon Folkes initiated coverage with a Buy rating and a price target of $8, while shares closed at $2.16.

  • Compass Therapeutics, Inc.: Canaccord Genuity analyst John Newman also initiated coverage with a Buy rating and a price target of $10, with shares closing at $5.22.

  • Linde plc and Others: CICC analyst Shanshan Shen rated Linde plc as Outperform with a price target of $510, and HC Wainwright initiated coverage on Pelthos Therapeutics and LifeSci Capital on Oculis Holding, both with positive ratings and significant price targets.

[object Object]
Preview
4.0
12-03Yahoo Finance
Cantor Fitzgerald Begins Coverage of Compass Therapeutics with an Overweight Rating
  • Company Overview: Compass Therapeutics (CMPX) has received an average rating of "buy" from analysts.
  • Price Target: The mean price target for CMPX is set at $12.62.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Compass Therapeutics Inc. (CMPX) stock price today?

The current price of CMPX is 5.54 USD — it has increased 4.92 % in the last trading day.

arrow icon

What is Compass Therapeutics Inc. (CMPX)'s business?

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.

arrow icon

What is the price predicton of CMPX Stock?

Wall Street analysts forecast CMPX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPX is 15.33 USD with a low forecast of 10.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Compass Therapeutics Inc. (CMPX)'s revenue for the last quarter?

Compass Therapeutics Inc. revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Compass Therapeutics Inc. (CMPX)'s earnings per share (EPS) for the last quarter?

Compass Therapeutics Inc.. EPS for the last quarter amounts to -0.08 USD, decreased -0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Compass Therapeutics Inc. (CMPX)'s fundamentals?

The market is revising No Change the revenue expectations for Compass Therapeutics, Inc. (CMPX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 61.05%.
arrow icon

How many employees does Compass Therapeutics Inc. (CMPX). have?

Compass Therapeutics Inc. (CMPX) has 35 emplpoyees as of December 05 2025.

arrow icon

What is Compass Therapeutics Inc. (CMPX) market cap?

Today CMPX has the market capitalization of 985.36M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free